This pilot study of immunogenicity of a TLR3 agonist in combination with helper T cell stimulation as adjuvants to traditional class I peptides showed that novel adjuvants can be safely combined with multi-peptide vaccines in the high risk breast cancer setting. The gene discussed is TLR3; the disease is breast cancer.